新天药业：接受财通基金等投资者调研

Group 1 - The core viewpoint of the article is that Xintian Pharmaceutical (SZ 002873) has engaged with investors through a research meeting, indicating active investor relations and transparency [1] - For the first half of 2025, Xintian Pharmaceutical reported that its main revenue accounted for 99.9% of total revenue, with other business activities contributing only 0.1% [1] - As of the report date, Xintian Pharmaceutical has a market capitalization of 3.1 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to positive performance among listed companies in this sector [1]